News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Bevacizumab (Avastin) for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.


Posted on: 03/10/2008

Neurology. 2008 Mar 4;70(10):779-87.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and
patterns of recurrence.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL,
Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.

Department of Neurology, Dana-Farber/Brigham and Women's Cancer
Center and Harvard Medical School, SW430B, 44 Binney St., Boston, MA
02115, USA. anorden@partners.org

BACKGROUND: Bevacizumab, a humanized monoclonal antibody against
vascular endothelial growth factor, may have activity in recurrent
malignant gliomas. At recurrence some patients appear to develop
nonenhancing infiltrating disease rather than enhancing tumor. METHODS:
We retrospectively reviewed 55 consecutive patients with recurrent
malignant gliomas who received bevacizumab and chemotherapy to determine
efficacy, toxicity, and patterns of recurrence. Using a blinded,
standardized imaging review and quantitative volumetric analysis, the
recurrence patterns of patients treated with bevacizumab were compared
to recurrence patterns of 19 patients treated with chemotherapy alone.
RESULTS: A total of 2.3% of patients had a complete response, 31.8%
partial response, 29.5% minimal response, and 29.5% had stable disease.
Median time to radiographic progression was 19.3 weeks. Six-month
progression-free survival (PFS) was 42% for patients with glioblastoma
and 32% for patients with anaplastic glioma. In 23 patients who
progressed on their initial therapy, bevacizumab was continued and the
concurrent chemotherapy agent changed. In no case did the change produce
a radiographic response, but two patients had prolonged PFS of 20 and 31
weeks. Recurrence pattern analysis identified a significant increase in
the volume of infiltrative tumor relative to enhancing tumor in
bevacizumab responders. CONCLUSIONS: Combination therapy with
bevacizumab and chemotherapy is well-tolerated and active against
recurrent malignant gliomas. At recurrence, continuing bevacizumab and
changing the chemotherapy agent provided long-term disease control only
in a small subset of patients. Bevacizumab may alter the recurrence
pattern of malignant gliomas by suppressing enhancing tumor recurrence
more effectively than it suppresses nonenhancing, infiltrative tumor
growth.


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740